Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sodium stibogluconate may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. Interferon alfa-2b may interfere with the growth of tumor
cells and slow the growth of melanoma and other cancers. Drugs used in chemotherapy, such as
cisplatin, vinblastine, and dacarbazine, work in different ways to stop the growth of tumor
cells, either by killing the cells or by stopping them from dividing. Giving sodium
stibogluconate and interferon alfa-2b together with combination chemotherapy may kill more
tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of sodium
stibogluconate when given together with interferon alfa-2b, cisplatin, vinblastine, and
dacarbazine in treating patients with advanced melanoma or other cancer.